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Tbjective: Despite its proven value in reducing thrombotic complications in patients
ndergoing coronary artery bypass graft surgery, aspirin does not reduce the incidence
f late vein graft failure. It was suggested, therefore, that co-administration of nitric
xide with aspirin may compensate for these limitations. A drug class that fulfills this
harmacologic criterion is nitric oxide–donating aspirin (NCX 4016).
ethods: The effect of administration of the aspirin–nitric oxide adduct, NCX 4016,
ompared with those of aspirin alone and the nitric oxide donor, morpholinosyd-
onimine, alone (once daily for 1 month) on thickening of saphenous vein-carotid
rtery interposition grafts was investigated.
esults: NCX 4016, at 10 mg, 30 mg, and 60 mg · kg1 · d1, inhibited neointimal
hickness and area in porcine vein grafts. Aspirin alone (60 mg · kg1 · d1) and
orpholinosydnonimine alone (1 mg · kg1 · d1), also inhibited neointimal
hickness and neointimal area, although they were less potent than NCX 4016. At
0 mg · kg1 · d1, aspirin had no effect. Compared with untreated controls, NCX 4016
ad little effect on medial thickness or area at 10 mg/kg or 30 mg · kg1 · d1 but had
significant effect at 60 mg · kg1 · d1. Aspirin alone and morpholinosydnonimine
lone also inhibited medial thickness and area. NCX 4016 at 60 mg · kg1 · d1 and
spirin at 60 mg · kg1 · d1 increased luminal area.
onclusions: The range of properties displayed by NCX 4016 (inhibition of neo-
ntima formation, gastroprotection, antithrombotic and antiatherogenic effects) ren-
ers them potentially useful in treating both early and late vein graft failure and
ndicates that a clinical study on this novel drug class in patients undergoing
oronary bypass grafting is warranted.
ein graft thickening and superimposed atherogenesis are the main causes of
late failure after coronary artery bypass graft (CABG) surgery with autol-
ogous saphenous vein.1 Vein graft thickening is determined by increased
eointima formation and medial thickening, both of which involve the proliferation
nd migration of vascular smooth muscle cells (VSMCs).2 Superimposed on these
apid events is atherogenesis, which ultimately leads to graft occlusion in as many
s 50% of cases within 10 years.1 Although internal thoracic and radial arteries are
ncreasingly being used instead of saphenous vein as a conduit, the percentage of
ABG procedures using arteries is still less than 20% in the United Kingdom.3 The
aphenous vein will still be widely used in the future for CABG. Apart from
ggressive lipid-lowering therapy,4 there is no effective therapeutic intervention for
ate vein graft failure,4 which constitutes a considerable clinical problem that needs
o be urgently resolved.
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CSPAspirin (ASA) is the most widely investigated drug in
atients undergoing CABG.5 Although ASA reduces the
ncidence of vein graft thrombosis in both the short and long
erm, it does not improve vein graft patency between 1 and
years after bypass surgery.1,5 Because of its antithrom-
otic effects, however, ASA is routinely administered to
atients after CABG and continued indefinitely thereafter.1,5
he relative lack of effect of ASA on late graft failure has
een ascribed to minimal effects on VSMC proliferation,
therogenesis, and plaque development, the principal causes
f late vein graft failure.1,2,5-7 ASA also promotes gastric
rosion and ulceration8 and inhibits vascular prostacyclin
ormation.9 Furthermore, 5% to 9% of patients are “ASA
esistant” and 23% are ASA “semi-responders.”10
In contrast to ASA, nitric oxide (NO) inhibits platelet
nd leukocyte adhesion and release of mitogens, VSMC
roliferation, promotes vasodilation, inhibits neointima for-
ation, and is gastroprotective.11 It was suggested, there-
ore, that the co-administration of an NO donor may com-
ensate for the limitations of ASA.6 A novel drug type that
ntrinsically fulfills this pharmacologic criterion is the group
f NO-releasing aspirins (NO-ASA).7,12,13 NO-donating as-
irins (but not ASA) inhibit the proliferation of VSMCs
erived from human saphenous veins and promote relax-
tion of human isolated saphenous vein.6 These effects are
ediated through the formation of cyclic guanosine mono-
hosphate, indicating that the active moiety of NO-ASA is
O.7 Furthermore, the NO-ASA, NCX 4016, inhibits neo-
ntima formation in balloon-injured carotid arteries in the
yperlipidemic mouse.14 In man, NCX 4016 inhibits plate-
et aggregation, releases NO into the blood for up to 10
ours after administration, reduces blood pressure, and pro-
ides gastroprotection.13
To determine whether NO-ASA may be of potential
enefit in preventing late vein graft failure through an a
riori inhibition of neointima formation, we studied the
ffect of the oral administration of NCX 4016 on neoin-
ima formation, medial thickening, and luminal area in
aphenous vein– carotid artery interposition grafts 1
onth after surgery in the pig. One month is appropriate
nasmuch as, in this model, neointima formation is max-
Abbreviations and Acronyms
ASA  aspirin
CABG coronary artery bypass graft
NCX  nitric oxide–donating aspirin
NO  nitric oxide
PCNA  proliferating cell nuclear antigen
SIN-1 morpholinosydnonimine
VSMC vascular smooth muscle cellmal at 1 month after vein implantation and does not p
034 The Journal of Thoracic and Cardiovascular Surgery ● Octncrease over ensuing months.15 The effect of oral ad-
inistration of ASA alone and the NO donor morpholi-
osydnonimine (SIN-1) were also studied because these
epresent the bioactive moieties of NCX 4016.
aterials and Methods
urgical Procedure
tudies were performed in 64 male Landrace pigs (8 controls, 56
reated) weighing 30 to 35 kg, which received humane care ac-
ording to the Home Office Animals Care regulations. Ethical
pproval had been obtained from the local committee at the Uni-
ersity of Bristol. All animals underwent saphenous vein–carotid
rtery interposition grafting.16,17 Anesthesia was induced with
etamine (30 mg) and atropine (0.6 mg) administered intramuscu-
arly. After endotracheal intubation, anesthesia was maintained
ith halothane and oxygen and animals were allowed to ventilate
pontaneously throughout. Heparin sodium (1 mg/kg) was admin-
stered intravenously, and a single dose of 250 mg of benzyl
enicillin was administered intramuscularly before skin incision. A
ongitudinal incision was made on the outer aspect of the hind
imb. Approximately 10 cm of the vein was then dissected free of
urrounding tissue. Care was taken not to remove the adventitia.
ll side branches were secured with a 6-0 polypropylene ligature
Prolene; Ethicon Inc, Somerville, NJ). The vein was removed
rom the animal, rinsed in iso-osmotic sodium chloride solution
0.9 g/L) containing 2 IU/mL heparin and 50 g/mL glyceryl
rinitrate, and stored in the same solution at room temperature
23°C) until needed.
A longitudinal neck incision was made just medial to the
ternocleidomastoid muscle, and the common carotid artery was
arefully dissected from the internal jugular vein and vagus nerve
ithin the carotid sheath. A 3-cm segment of the common carotid
rtery was isolated between vascular clamps and excised, beveling
he cut ends obliquely to 45°C. The saphenous vein was cut to the
ppropriate length, reversed and similarly beveled, and an end-to-
nd anastomosis of the vein to the common carotid artery was
arried out with a continuous 7-0 polypropylene suture. Animals
ere extubated and, when in a satisfactory condition, returned to
heir pens and fed a normal chow diet.
rug Administration
CX 4016 was supplied by NiCox SA (Nice, France). Nitroaspi-
ins are stable nitrate-ester compounds that require enzymatic
ydrolysis to liberate NO.12 The kinetics of this metabolic pro-
essing leads to durable production of NO released at a constant
ate from the site of metabolism.12 NCX 4016 (30 and 60 mg ·
g1 · d1), aspirin (30 and 60 mg · kg1 · d1; Sigma Chemical
o, Poole, Dorset, United Kingdom), or SIN-1 (1 mg · kg1 · d1;
igma) were all fed to pigs (8 per treatment group), once daily,
ncorporated into small amounts of mashed potatoes to ensure
omplete ingestion of drugs. Drug treatment was commenced 1
ay before surgery. Animals were randomized such that surgery
as carried out alternately on each dose of drug and drug type.
ach graft was removed, including 1-cm segments of the proximal
nd distal carotid arteries, pressure fixed ex vivo at 100 mm Hg
ith Carson fixative, and postfixed in the same solution for ap-
roximately 24 hours before being processed for wax embedding.
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Prafts were deemed patent when they had not occluded as a result
f thrombosis.
istologic Analysis
istologic studies of vein grafts were carried out as previously
escribed.16,17 Sections were dewaxed, rehydrated, and stained
ith hematoxylin and eosin or Miller elastic van Gieson stain. For
roliferating cell nuclear antigen (PCNA), sections were dewaxed,
ehydrated, and treated with hydrogen peroxide in methanol to
emove endogenous peroxidase, and the following staining was
arried out. Sections were microwaved in citrate buffer, quenched
n 1:3 horse serum in triethanolamine-buffered saline, and then
ncubated with PCNA antibody diluted 1:100 overnight at 4°C.
ections were washed and then treated with 1:400 biotinylated
oat antimouse antibody followed by streptavidin, biotinylated
orseradish peroxidase detection solution. Visualization was
chieved with 3,3=-diaminobenzidine; then, after being counter- d
The Journal of Thoracictained with diluted hematoxylin and eosin, sections were dehy-
rated and mounted.
orphometric Analysis
essel wall dimensions were measured by computer-aided
lanimetry using an Olympus BH-2 microscope with a color
ideo camera head (JVC TK-870E; JVC, Yokohama, Japan)
oupled to a Microscale TM/TC image analysis system (Dig-
thurst Ltd, Royston, United Kingdom). The area enclosed by
he endothelium and the internal elastic lamina defined the
ntima, and the area between the internal and external elastic
amina defined the media. Luminal, intimal, and medial perim-
ters and areas were computed with the luminal boundary and
he internal and external elastic lamina as delimiters, and mean
alues were then calculated for all sections from the same graft.
verage intimal, medial, and total vessel wall thickness was
Figure 1. Planimeteric analysis of neointimal
thickness (A) and area (B) of vein grafts from pigs
to which nitroaspirin 4016 (NCX), aspirin alone
(ASA), or morpholinosydnonimine (SIN-1) alone
was administered orally, once daily for 1 month.
Doses, as milligrams per kilogram per day, are
indicated below drug name. Data are expressed
as medians and interquartile ranges (n  8).
Statistical significance was determined by a
Mann–Whitney test with a Bonferroni adjust-
ment. Using the Kendall tau-b test, significant
dose-response relationships were obtained for
NCX-treated grafts versus controls for both neo-
intimal thickness (P< .05) and neointimal area (P
< .05). CON, Control; SV, saphenous vein; VG,
vein graft; ns, not significant.erived from the area and perimeter data for 5 sections from
and Cardiovascular Surgery ● Volume 134, Number 4 1035
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CSP
ach graft, assuming that the sections consisted of circular
rofiles, which was a valid assumption because the tissues were
xed at normal perfusion pressure.
ata Analysis and Statistics
ata were collated and analyzed by Microsoft Excel (Microsoft
orporation, Redmond, Wash) and nonparametric statistical anal-
sis was carried out with an Intercooled Stata 8 statistics package
Stata Corporation, College Station, Tex). The Barlett test for
quality of variance (a necessary assumption for a one-way anal-
sis of variance) was significant, indicating that nonparametric
ethods of analysis were required for morphometric appraisal of
ein grafts and PCNA. Thus, values are expressed as median and
5th and 75th interquartile ranges and graphically as box and
hisker plots. Mann–Whitney U tests were then applied to test thetatistical significance between control and treated groups. To test d
036 The Journal of Thoracic and Cardiovascular Surgery ● Octhether drug effects were dose dependent, we used the Kendall
au-b test as a measure of correlation for ordinal categorical data,
hich takes ties into account.
esults
ll grafts were patent 4 weeks after implantation. There was
significant increase in the luminal area, neointimal thick-
ess and area, medial thickness and area, and luminal area
n vein grafts from untreated animals compared with un-
rafted saphenous veins (Figures 1 to 3).
Administration of NCX 4016 at 10, 30, and 60 mg ·
g1 · d1 elicited a dose-dependent inhibitory effect on
eointimal thickness and area when assessed at 1 month
fter implantation (Figure 1). Both ASA alone (60 mg · kg1 ·
Figure 2. Planimeteric analysis of medial thick-
ness (A) and medial area (B) of vein grafts from
pigs which nitroaspirin 4016 (NCX), aspirin
alone (ASA), or morpholinosydnonimine (SIN-1)
alone was administered orally, once daily for 1
month. Doses, as milligrams per kilogram per
day, are indicated below drug name. Data are
expressed as medians and interquartile ranges
(n  8). Statistical significance was determined
by a Mann–Whitney test with a Bonferroni ad-
justment. Using the Kendall tau-b test, no signif-
icant dose–response relationships were ob-
tained. CON, Control; SV, saphenous vein; VG,
vein graft; ns, not significant.1) and SIN-1 alone (1 mg · kg1 · d1), also inhibited neoin-
ober 2007
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Pimal thickness and area (Figure 1). By contrast, ASA alone at 30
g · kg1 · d1 had no effect on neointimal thickness (Figure
). Compared with untreated controls, administration of NCX
016 had no significant effect on medial thickness at 10 or 30
g · kg1 · d1 but had a significant effect at 60 mg · kg1 ·
1 (Figure 2). ASA alone and SIN-1 alone also inhibited
edial thickness and area (Figure 2). NCX 4016 and SIN-1
ad no significant effect on luminal area, whereas ASA
lone at 60 mg · kg1 · d1 significantly increased luminal
rea (Figure 3). Administration of NCX 4016 at 10, 30, andThe Journal of Thoracic0 mg · kg1 · d1 and SIN-1 alone (1 mg · kg1 · d1) elicited
dose-dependent inhibitory effect on PCNA count (Figure 4).
y contrast, ASA alone at 30 and 60 mg · kg1 · d1 had no
ffect on PCNA count (Figure 4).
iscussion
he present study demonstrates that at doses as low as
0 mg · kg1 · d1 for 1 month, NCX 4016 inhibits
eointima formation and cell replication in porcine saphe-
ous vein grafts. SIN-1, an NO donor, at 1 mg · kg1 · d1,
Figure 3. Planimeteric analysis of luminal area
of vein grafts from pigs to which nitroaspirin 4016
(NCX), aspirin (ASA), or morpholinosydnonimine
(SIN-1) was administered orally, once daily for 1
month. Doses, as milligrams per kilogram per
day, are indicated below drug name. Data are
expressed as medians and interquartile ranges
(n  8). Statistical significance was determined
by a Mann–Whitney test with a Bonferroni ad-
justment. Using the Kendall tau-b test, no signif-
icant dose–response relationships were ob-
tained. CON, Control; SV, saphenous vein; VG,
vein graft; ns, not significant.
Figure 4. Percentage of cells with proliferating
cell nuclear antigen (PCNA)–positive nuclei rel-
ative to PCNA-negative nuclei in the intimal/
medial regions of vein grafts from pigs to which
nitroaspirin 4016 (NCX), aspirin (ASA), or mor-
pholinosydnonimine (SIN-1) was administered
orally, once daily for 1 month. Doses, as milli-
grams per kilogram per day, are indicated below
drug name. Data are expressed as medians and
interquartile ranges (n  8). Statistical signifi-
cance was determined by a Mann–Whitney test
with a Bonferroni adjustment. Using the Kendall
tau-b test, significant dose–response relation-
ships were obtained for NCX 4016-treated grafts
versus controls for luminal area (P < .05). CON,
Control; SV, saphenous vein; VG, vein graft; ns,
not significant.and Cardiovascular Surgery ● Volume 134, Number 4 1037
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CSPlso had a marked inhibitory effect on neointima forma-
ion. Although ASA also had a significant effect at
0 mg · kg1 · d1, it had no effect at 30 mg · kg1 · d1
at which dose NCX 4016 still elicited a marked inhibitory
ffect on neointimal thickening). The effect of ASA at 60
g · kg1 · d1 was less than that of NCX 4016 at even 10
g · kg1 · d1. It is likely, therefore, that the present effect
f NCX 4016 on neointima formation is due to the NO
oiety of the drug. Indeed, many studies have demonstrated
hat NO donors or gene transfer of NO synthetase inhibits
eointima formation.11 Neointima formation involves the
igration of VSMCs to the intima.2 In turn, NO is a potent
nhibitor of VSMC migration,11 which would also explain,
t least in part, the present inhibitory in vivo effect of NCX
016 on neointima formation. NCX 4016 elicits effects
hrough both ASA- and NO-mediated mechanisms. These
nclude the inhibition of platelet function, inhibition of
eutrophil adherence, a reduction of blood pressure, and
astroprotection.13,18-20 In plasma, NCX 4016 releases NO
n vivo, assessed as a mixture of nitrites and nitrates, for up
o 10 hours after administration.13
Other studies on the effect of ASA administration in
nimal models have yielded equivocal results in that the
dministration of doses of ASA between 175 and 325 mg/d
ither have been shown to inhibit neointima formation21,22
r have no effect.23,24 Also, ASA does not directly inhibit
SMC proliferation, a central component of neointima for-
ation.7 This may indicate that ASA inhibits neointima
ormation through an inhibition of platelet function. Cer-
ainly, platelet adhesion is an immediate consequence of
ein graft implantation and, owing to endothelial damage, is
ighly aggressive.6 This can lead to early vein graft failure
wing to thrombosis within days after CABG surgery.1,6
latelets release a large number of VSMC mitogens, includ-
ng serotonin, platelet activating factor, thromboxane A2,
nd peptide growth factors.6 It follows, therefore, that the
nhibition of platelet adhesion may prevent the local release
f these mitogens, which would explain the inhibitory effect
f ASA at 60 mg · kg1 · d1 on neointima formation.
owever, at 30 mg · kg1 · d1, a dose at which platelet
unction is almost certain to be inhibited, ASA had no effect
n neointima formation. This indicates that platelets do not
lay a role in mediating neointima formation. One possible
xplanation for this effect of high-dose ASA is that at high
oncentrations ASA inhibits signal transduction systems
hat inhibit cell replication, in particular nuclear factor
appa B.25 However, these very high doses of ASA would
arkedly compromise the well-being of bypass patients
hrough gastric erosion.
A notable finding of the present study was that NCX
016 and SIN-1 had a minimal effect on medial thickening
f porcine vein grafts, whereas ASA at 60 mg · kg1 · d1
but not 30 mg · kg1 · d1) had a marked inhibitory effect f
038 The Journal of Thoracic and Cardiovascular Surgery ● Octhat was reflected by the large increase in luminal area.
owever, medial thickening is an inevitable and an actually
esirable adaptation of a saphenous vein graft anastomosed
nto coronary arterial beds.26 Overdistention by this high
ose of ASA may create aneurysmal abnormalities of flow,
ncluding vortices and stasis, both of which contribute to
hrombogenesis.27,28
NCX 4016 possesses antiatherogenic properties, the cen-
ral long-term lesion in late vein graft failure that is super-
mposed on the neointima. Most notably, NCX 4016 sig-
ificantly inhibited macrophage density in injured vessels in
hypercholesterolemic mouse model.14 This probably re-
ates to the NO moiety of NCX 4016 inasmuch as NO (but
ot ASA) inhibits adhesion molecule expression in mono-
ytes.14 Other antiatherogenic properties of NCX 4016 in-
lude the inhibition of tissue factor expression, superoxide
ormation, reduced nicotinamide adenine dinucleotide phos-
hate oxidase expression, cytokine release, and caspase
ctivity, all of which are mediated by the NO moiety of the
rug.13,29 Thus, NCX 4016 possesses the potential to ame-
iorate atherogenesis in vein grafts if used over protracted
eriods.
NCX 4016 also has the additional advantage of being an
ffective antithrombotic agent through its intrinsic ASA
ctivity.18 Certainly, between 3% and 12% of saphenous
ein grafts occlude, with or without symptoms, within the
rst month after CABG surgery.1 Of course, NO itself is
otent inhibitor of platelet activity.6 NCX 4016 would pre-
ent gastric erosion associated with long-term administra-
ion of ASA. Thus far in all clinical trials reported, NCX
016 has been shown to elicit minimal side effects.13
Thus, given the range of therapeutic properties relevant
o vein graft failure and the limitations of ASA, clinical
rials on NCX 4016 in patients undergoing CABG are
ndicated. Although arteries such as internal thoracic and
adial are increasingly being used instead of saphenous vein
s a conduit, the percentage of CABG operations in which
rteries are used is still less 20% in the United Kingdom;
hus, the saphenous vein will still be widely used in the
uture. From an investigative perspective, effects on graft
hickening would be assessed by intravascular ultrasound at
months or 1 year after CABG. As mentioned, a significant
umber of patients are “aspirin resistant” or are semi-
esponders.10 It is possible that NCX 4016 may compen-
ate for this considerable problem inasmuch as NO also
nhibits platelet function. Thus, in a clinical trial, platelet
unction tests and related thombotic profiles should be
ssessed before surgery. Effects on oxidative stress, the
ctivity of monocytes (the progentors of plaques), and the
ctivity of neutrophils should also be assessed in such a
rial.
We thank Dr Rosemary Greenwood, Bristol Royal Infirmary,
or her expert advice on statistics.
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